Cullinan Therapeutics, Inc. (CGEM) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Cullinan Therapeutics, Inc. (CGEM) Earnings Overview
As of June 22, 2026, Cullinan Therapeutics, Inc. (CGEM) reported trailing twelve-month net income of -$221M, reflecting -19.6% year-over-year growth. The company earned $-3.73 per diluted share over the past four quarters.
Looking at the long-term picture, CGEM's historical earnings data spans multiple years. The company achieved its highest annual net income of $111M in fiscal 2022.
Cullinan Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), KYMR (-$315M net income, -794.4% margin), RCUS (-$369M net income, -142.9% margin), CGEM has comparable earnings metrics. Compare CGEM vs IMVT →
CGEM Earnings vs Peers
Earnings metrics vs comparable public companies
CGEM Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$220M | -31.4% | -$242M | $-3.72 | - | - |
| 2024 | -$167M | -9.3% | -$197M | $-3.11 | - | - |
| 2023 | -$153M | -237.7% | -$191M | $-3.69 | - | - |
| 2022 | $111M | +269.6% | $145M | $2.38 | - | - |
| 2021 | -$66M | -26.6% | -$68M | $-1.48 | -346.1% | -358.7% |
| 2020 | -$52M | -158.5% | -$60M | $-1.19 | - | - |
| 2019 | -$20M | -41.2% | -$22M | $-19.68 | - | - |
| 2018 | -$14M | - | -$15M | $-17.74 | - | - |
Download Data
Export CGEM earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CGEM — Frequently Asked Questions
Quick answers to the most common questions about buying CGEM stock.
What is CGEM earnings per share (EPS)?
CGEM trailing twelve-month (TTM) diluted EPS is $-3.73, reflecting -19.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Cullinan Therapeutics, Inc.'s net income?
Cullinan Therapeutics, Inc. (CGEM) trailing twelve-month net income is $-221M as of 2025. Earnings declined -19.6% year-over-year.
Is CGEM profitable?
CGEM is not currently profitable on a TTM basis, reporting a net loss of $-221M. Net margin is N/A. Investors should monitor for a return to profitability.
What is CGEM's earnings growth rate?
CGEM compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are CGEM's profit margins?
Cullinan Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -44.0%.
Is CGEM growing earnings?
CGEM earnings are declining — EPS fell -19.6% year-over-year. TTM net income dropped to $-221M. This contrasts with the 5-year CAGR of N/A.
What was CGEM's best earnings year?
Cullinan Therapeutics, Inc.'s highest annual net income on record is $111M, achieved in fiscal year 2022. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were CGEM's earnings last quarter?
CGEM's most recent reported quarter was Q1 2026. Net income was $-50M with diluted EPS of $-0.84. For a full breakdown of all quarters, see the quarterly earnings table on this page.